ProfileGDS5678 / 1420850_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 89% 89% 90% 89% 91% 90% 90% 88% 89% 90% 90% 88% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.89989
GSM967853U87-EV human glioblastoma xenograft - Control 27.1629189
GSM967854U87-EV human glioblastoma xenograft - Control 37.1201689
GSM967855U87-EV human glioblastoma xenograft - Control 47.3641390
GSM967856U87-EV human glioblastoma xenograft - Control 57.0276989
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.2162291
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.0260790
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.2514890
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8630188
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.1393689
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.1892390
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.3626890
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.7760288
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.3585191